Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
Subscribe To Our Newsletter & Stay Updated
